CO2023016088A2 - Compuestos de espiroindolinona como bloqueadores del canal agitador de potasio kv1.3 - Google Patents
Compuestos de espiroindolinona como bloqueadores del canal agitador de potasio kv1.3Info
- Publication number
- CO2023016088A2 CO2023016088A2 CONC2023/0016088A CO2023016088A CO2023016088A2 CO 2023016088 A2 CO2023016088 A2 CO 2023016088A2 CO 2023016088 A CO2023016088 A CO 2023016088A CO 2023016088 A2 CO2023016088 A2 CO 2023016088A2
- Authority
- CO
- Colombia
- Prior art keywords
- potassium
- channel blockers
- shaker channel
- spiroindolinone
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 title 1
- 229910052700 potassium Inorganic materials 0.000 title 1
- 239000011591 potassium Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Se describe un compuesto de la Fórmula I ( ) o una sal farmacéuticamente aceptable de este en donde los sustituyentes son como se definen en la presente descripción. También se describen composiciones farmacéuticas que 5 comprenden el mismo y el método de uso del mismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163194599P | 2021-05-28 | 2021-05-28 | |
| PCT/US2022/031229 WO2022251561A2 (en) | 2021-05-28 | 2022-05-27 | Spiroindolinone compounds as kv1.3 potassium shaker channel blockers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023016088A2 true CO2023016088A2 (es) | 2024-02-26 |
Family
ID=84230386
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0016088A CO2023016088A2 (es) | 2021-05-28 | 2023-11-23 | Compuestos de espiroindolinona como bloqueadores del canal agitador de potasio kv1.3 |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP4351569A2 (es) |
| JP (1) | JP2024522280A (es) |
| KR (1) | KR20240001192A (es) |
| CN (1) | CN117597120A (es) |
| AR (1) | AR125994A1 (es) |
| AU (1) | AU2022281402A1 (es) |
| BR (1) | BR112023023951A2 (es) |
| CA (1) | CA3219345A1 (es) |
| CO (1) | CO2023016088A2 (es) |
| CR (1) | CR20230555A (es) |
| DO (1) | DOP2023000257A (es) |
| EC (1) | ECSP23089582A (es) |
| IL (1) | IL308277A (es) |
| TW (1) | TW202310831A (es) |
| WO (1) | WO2022251561A2 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023141432A2 (en) | 2022-01-18 | 2023-07-27 | Maze Therapeutics, Inc. | Apol1 inhibitors and methods of use |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4345081A (en) * | 1980-02-15 | 1982-08-17 | American Hoechst Corporation | Spiro[indoline-3,4'-piperidine]s |
| EP2108641A1 (en) * | 2008-04-11 | 2009-10-14 | Laboratorios Almirall, S.A. | New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors |
-
2022
- 2022-05-27 EP EP22812208.1A patent/EP4351569A2/en active Pending
- 2022-05-27 KR KR1020237040381A patent/KR20240001192A/ko active Search and Examination
- 2022-05-27 BR BR112023023951A patent/BR112023023951A2/pt unknown
- 2022-05-27 TW TW111119802A patent/TW202310831A/zh unknown
- 2022-05-27 AU AU2022281402A patent/AU2022281402A1/en active Pending
- 2022-05-27 CN CN202280038587.8A patent/CN117597120A/zh active Pending
- 2022-05-27 AR ARP220101414A patent/AR125994A1/es unknown
- 2022-05-27 CR CR20230555A patent/CR20230555A/es unknown
- 2022-05-27 CA CA3219345A patent/CA3219345A1/en active Pending
- 2022-05-27 WO PCT/US2022/031229 patent/WO2022251561A2/en active Application Filing
- 2022-05-27 IL IL308277A patent/IL308277A/en unknown
- 2022-05-27 JP JP2023573161A patent/JP2024522280A/ja active Pending
-
2023
- 2023-11-23 CO CONC2023/0016088A patent/CO2023016088A2/es unknown
- 2023-11-24 DO DO2023000257A patent/DOP2023000257A/es unknown
- 2023-11-27 EC ECSENADI202389582A patent/ECSP23089582A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CR20230555A (es) | 2024-02-19 |
| AR125994A1 (es) | 2023-08-30 |
| CN117597120A (zh) | 2024-02-23 |
| KR20240001192A (ko) | 2024-01-03 |
| EP4351569A2 (en) | 2024-04-17 |
| WO2022251561A2 (en) | 2022-12-01 |
| WO2022251561A3 (en) | 2023-01-05 |
| TW202310831A (zh) | 2023-03-16 |
| IL308277A (en) | 2024-01-01 |
| ECSP23089582A (es) | 2023-12-29 |
| BR112023023951A2 (pt) | 2024-01-30 |
| JP2024522280A (ja) | 2024-06-13 |
| CA3219345A1 (en) | 2022-12-01 |
| AU2022281402A1 (en) | 2023-11-02 |
| DOP2023000257A (es) | 2023-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP20044709A (es) | Inhibidores de sarcómero cardíaco | |
| CO2021015698A2 (es) | Moduladores de thr-β y métodos de uso de estos | |
| CO2023016088A2 (es) | Compuestos de espiroindolinona como bloqueadores del canal agitador de potasio kv1.3 | |
| UY39526A (es) | Inhibidores de kras g12d | |
| CL2021000481A1 (es) | Inhibidores de sarcómeros cardíacos. | |
| CR20230115A (es) | Compuestos heterocíclicos | |
| CO2022004305A2 (es) | Compuestos heterocíclicos de arilmetileno como bloqueadores del canal shaker de potasio kv1.3 | |
| CL2023002616A1 (es) | Inhibidores del sarcómero cardíaco | |
| CL2021002621A1 (es) | Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria | |
| CL2022002661A1 (es) | Derivados de benzodiazepinas como pam de gaba a gamma1 | |
| CL2022000893A1 (es) | Derivados de 2-azaspiro[3,4]octano como agonistas de m4 | |
| CO5601010A2 (es) | Derivados de oxazolidinona, procesos para su preparacion y composiciones farmaceuticas que los contienen | |
| MX2022004144A (es) | Compuestos heterobiciclicos de arilo como bloqueadores del canal de potasio tipo shaker kv1.3. | |
| CL2023001440A1 (es) | Nuevos derivados de indazol acetileno | |
| UY38567A (es) | Inhibidores de o-glucoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa de éter bicíclico | |
| CO2023013052A2 (es) | Compuestos heterocíclicos de arilo como bloqueadores del canal agitador de potasio kv1.3 | |
| AR116428A1 (es) | Compuestos de 6-fluoro-2-metilbenzo[d]tiazol-5-ilo | |
| MX2022004178A (es) | Compuestos heterobiciclicos de arilo como bloqueadores del canal de potasio tipo shaker kv1.3. | |
| UY38498A (es) | Inhibidores de o-glucoproteina-2- acetamido-2-desoxi-3-d-glucopiranosidasa de morfolinilo , piperazinilo , oxazepanilo y diazepanilo | |
| AR127559A1 (es) | Compuestos, composiciones y métodos | |
| CO2022006942A2 (es) | Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria | |
| CO2024005362A2 (es) | Compuestos de cd73 | |
| AR124698A1 (es) | Derivados tricíclicos útiles como inhibidores de parp7 | |
| ECSP23075535A (es) | Compuestos cíclicos y métodos de uso | |
| CO2024002909A2 (es) | Derivado de triazol sustituido, método de preparación del mismo, composición farmacéutica del mismo y uso del mismo |